MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Journal of Clinical Pharmacy and Therapeutics' source. Wed, 08 Feb 2012 14:04:18 +0100 http://www.medworm.com/index.php?rid=5505022&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01317.x Conclusion:  Although a significant inter‐patient difference in warfarin maintenance dose was observed between the CYP4F2 CC and CT genotypes, serum S‐warfarin concentration was not significantly different between them. An effect of CYP4F2 V433M polymorphism on warfarin maintenance dose was observed but was relatively small when compared to the effects of CYP2C9 and VKOR polymorphism. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5505022 Fri, 16 Dec 2011 05:00:00 +0100 5505022 http://www.medworm.com/index.php?rid=5552425&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01328.x We describe a systematic method for clinical pharmacists to record their activities and assess their value. This methodology should help in the development of clinical pharmacy in Spain and should be translatable to other settings. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5552425 Thu, 01 Dec 2011 05:00:00 +0100 5552425 http://www.medworm.com/index.php?rid=5538173&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01323.x Conclusion:  Vildagliptin is effective in glycaemic control with a low risk of hypoglycaemia and other adverse reactions. This may have an important impact on patient adherence to this medication. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5538173 Thu, 01 Dec 2011 05:00:00 +0100 5538173 http://www.medworm.com/index.php?rid=5515575&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01327.x Discussion:  The two systems performed well, achieving accuracies of approximately 80% and 90%, after being trained on only a small number of cases (126 and 244 cases, respectively). Through analysis of the available data, it was estimated that without the system intervening, the expert training the first prototype would have missed approximately 36% of potentially relevant DRPs, and the second 43%. However, the system appeared to prevent the majority of these potential expert errors by correctly identifying the DRPs for them, leaving only an estimated 8% error rate for the first expert and 4% for the second.What is new and conclusion:  These intelligent decision support systems have shown a clear potential to substantially improve the quality and consistency of medication reviews, whi... Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5515575 Thu, 01 Dec 2011 05:00:00 +0100 5515575 http://www.medworm.com/index.php?rid=5505021&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01324.x Conclusion:  Maintaining a therapeutic INR requires a dedicated multi‐faceted approach. With diligence, skill and various therapeutic strategies, a TTR >70% can be achieved. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5505021 Thu, 01 Dec 2011 05:00:00 +0100 5505021 http://www.medworm.com/index.php?rid=5487000&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01325.x Conclusion:  A population pharmacokinetic model was developed to characterize ABT‐594 concentrations in subjects with neuropathic pain. As ABT‐594 is primarily eliminated as unchanged drug in the urine, creatinine clearance and age were significant covariates of clearance with creatinine clearance being the optimal predictor of ABT‐594 clearance. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5487000 Thu, 01 Dec 2011 05:00:00 +0100 5487000 http://www.medworm.com/index.php?rid=5469097&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01316.x Conclusion:  Variation between objective and subjective assessments of the severity of possible errors indicated by safety events highlight the importance of distinguishing between, and using, both forms of assessment. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5469097 Thu, 01 Dec 2011 05:00:00 +0100 5469097 http://www.medworm.com/index.php?rid=5457893&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01322.x Conclusion:  This article offers recommendations designed to improve the robustness of evaluation when using expert opinion to evaluate CIs performed by community pharmacists. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5457893 Thu, 01 Dec 2011 05:00:00 +0100 5457893 http://www.medworm.com/index.php?rid=5457895&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01313.x Conclusion:  This study indicates that the antiplatelet effect of low‐dose aspirin can be markedly reduced with combined use of ibuprofen, depending on the timing of co‐administration. As even the lower OTC dose of ibuprofen (150 mg) was enough to affect the antiplatelet effect of aspirin, health professionals should take into account patients’ use of OTC ibuprofen when prescribing low‐dose aspirin. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5457895 Mon, 28 Nov 2011 05:00:00 +0100 5457895 http://www.medworm.com/index.php?rid=5457894&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01321.x Conclusion:  Severe and life‐threatening adverse reactions induced by ceftriaxone are of great concern. Rapid intravenous injection, unlabelled use and previous patient history of allergic reactions to cephalosporins or penicillins are risk factors that should be guarded against. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5457894 Mon, 28 Nov 2011 05:00:00 +0100 5457894 http://www.medworm.com/index.php?rid=5408304&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01314.x Conclusion: We describe the prevalence of clinically important DDIs in an emerging economy setting and identify the more common potentially serious DDIs. In line with the observations in developed economies, a higher number of episodes of DDIs were seen in patients aged ≥70 years and with more medications prescribed. The easiest method to reduce the frequency of DDIs is to reduce the number of medications prescribed. Therapeutic alternatives should be selected cautiously. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5408304 Wed, 16 Nov 2011 21:42:55 +0100 5408304 http://www.medworm.com/index.php?rid=5387107&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01320.x Conclusion:  We re‐emphasize a potentially serious, albeit very rare, adverse effect of ranitidine and summarize other reported cases. This case demonstrates that commonly used, generally safe drugs may on occasions cause serious adverse effects. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5387107 Thu, 10 Nov 2011 07:46:35 +0100 5387107 http://www.medworm.com/index.php?rid=5387110&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01315.x The objective of this study was to investigate the efficacy of landiolol hydrochloride, an ultra‐short‐acting β1‐blocker, in patients with post‐operative supraventricular tachycardia after pulmonary resection.Methods:  The response to continuous intravenous infusion of landiolol was evaluated in 25 patients who developed post‐operative atrial fibrillation or atrial flutter after major pulmonary resection. Four patients had preoperative rate‐controlled chronic atrial fibrillation. The heart rate and blood pressure were compared before and after infusion of landiolol. Side effects and recurrence of supraventricular tachycardia after termination of landiolol infusion were also monitored.Results and discussion:  The heart rate was reduced from 135 ± 24 bpm before landio... Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5387110 Mon, 07 Nov 2011 05:00:00 +0100 5387110 http://www.medworm.com/index.php?rid=5387109&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01318.x Conclusions:  Statin therapy in patients with first‐ever acute stroke lowers the risk of 6‐year stroke recurrence and improves survival in an aging Mediterranean cohort. These results add additional evidence in routine clinical practice to the observed effects of statins in clinical trials. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5387109 Mon, 07 Nov 2011 05:00:00 +0100 5387109 http://www.medworm.com/index.php?rid=5387108&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01319.x Conclusion:  The use of CAM in a subject with ARDs does not have significant benefits of overall survival but does somewhat improve quality of life. However, awareness of the provisions of the compensation scheme for CAM use in a population with ARDs should be carefully informed and also emphasized any side effects on progress of ARDs. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5387108 Mon, 07 Nov 2011 05:00:00 +0100 5387108 http://www.medworm.com/index.php?rid=5347687&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01300.x Conclusion:  Physicians should pay attention to adherence problems particularly when prescribing ACEI to male patients, those who are older than 70 years, have no comorbidity, live in less urbanized or more rural areas, qualify for fee‐waiver, are new attendees of consultations or obtain their ACEI prescriptions in FMSC. Future research should evaluate the reasons for ACEI discontinuation among these higher‐risk groups. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5347687 Wed, 26 Oct 2011 12:22:53 +0100 5347687 http://www.medworm.com/index.php?rid=5347688&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01290.x Conclusion:  There were several previous case reports on dyskinesia and dystonia associated with aripiprazole medication. The risk factors for tardive dyskinesia include older age and female sex. However, our case was a male patient who was younger compared with the previous cases and so should have been less at risk for dyskinesia in comparison with the previous cases. The effects of aripiprazole can include tardive movement disorders. Dyskinesia, dystonia and psychotic symptoms were improved with relatively small dose of quetiapine in this case. Whether some second‐generation antipsychotics are more effective than others in the treatment of tardive dyskinesia remains unclear. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5347688 Mon, 24 Oct 2011 04:00:00 +0100 5347688 http://www.medworm.com/index.php?rid=5347691&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01291.x Conclusion:  Teicoplanin, used as an alternative in cases of vancomycin intolerance, was associated with a high incidence of ADRs and haematological reactions, most notably neutropenia. This high rate of ADRs suggests cross‐reactivity between the two glycopeptides. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5347691 Sun, 23 Oct 2011 04:00:00 +0100 5347691 http://www.medworm.com/index.php?rid=5347690&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01311.x Conclusion:  There remains a large gap between Japan and Western countries, such as the USA and the UK, with regard to access to standard psychiatric drugs, despite several important reforms in the Japanese drug approval system. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5347690 Sun, 23 Oct 2011 04:00:00 +0100 5347690 http://www.medworm.com/index.php?rid=5347689&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01312.x Conclusion:  Treatment of leptospirosis with antibiotics, including the penicillin, remains controversial. The main benefit of using penicillin in the present study was a reduction in the length of hospital stay and fewer complications, such as AKI, but its use was not associated with a decrease in mortality. On balance of risks and benefits, we recommend the use of penicillin in late‐stage leptospirosis. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5347689 Sun, 23 Oct 2011 04:00:00 +0100 5347689 http://www.medworm.com/index.php?rid=5336023&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01308.x Conclusion:  Addressing the three identified facets of care within a new, collaborative post‐discharge warfarin management service may address the perceived deficiencies in existing systems. Improvements may result in the short‐ and longer‐term health outcomes of patients discharged from hospital taking warfarin, including a reduction in their risk of adverse events. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5336023 Thu, 20 Oct 2011 04:00:00 +0100 5336023 http://www.medworm.com/index.php?rid=5336022&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01309.x Conclusion:  This is the first report of pulmonary oedema attributable to an echinocandin antifungal agent. While such infusion‐related adverse events including pulmonary oedema appear uncommon, it is important for clinicians to be aware of this possibility and maintain the drug’s infusion rate to <1·1 mg/min and monitor for signs and symptoms of pulmonary oedema. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5336022 Thu, 20 Oct 2011 04:00:00 +0100 5336022 http://www.medworm.com/index.php?rid=5336021&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01310.x Conclusion: The dose range checking algorithm that we have derived from first principles will allow the clinical workflow and warnings to be constructed more effectively within systems to enhance patient safety. This will form a basis for the development of optimal schemes for adding decision support to prescribing systems. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5336021 Sat, 01 Oct 2011 04:00:00 +0100 5336021 http://www.medworm.com/index.php?rid=5304568&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01301.x Conclusion:  Psychotherapies can be conceptualized as epigenetic ‘drugs’, or at least as therapeutic agents that act epigenetically in a manner similar or complementary to drugs. These findings are leading to a paradigm shift in psychiatry such that psychotherapy is experiencing a come‐back as various standardized, brief, goal‐directed psychotherapies are being integrated with drug treatment of psychiatric disorders by psychopharmacologists who have traditionally relied on a drugs‐only approach. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5304568 Sat, 01 Oct 2011 04:00:00 +0100 5304568 http://www.medworm.com/index.php?rid=5285864&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01307.x Conclusion:  Food effects on ticagrelor AUC and AR‐C124910XX Cmax were small and are considered to be of minimal clinical significance. Thus, ticagrelor can be administered with or without food. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5285864 Sat, 01 Oct 2011 04:00:00 +0100 5285864 http://www.medworm.com/index.php?rid=5260909&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01302.x Conclusion:  Combination therapy that efficiently and effectively targets multiorgan correction with the least risk for serious adverse events, such as hypoglycaemia and drug interactions, is needed when initial treatment fails to achieve the desired clinical outcomes. Newer agents, now incorporated in treatment guidelines, increase the range of options available to the clinician. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5260909 Thu, 29 Sep 2011 05:30:08 +0100 5260909 http://www.medworm.com/index.php?rid=5260910&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01299.x Conclusion:  This study provides preliminary evidence that TBTR is at least as efficacious as CCT in reducing symptoms of SAD, pointing to the need for additional studies of TBTR in SAD and other psychiatric disorders. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5260910 Wed, 28 Sep 2011 04:00:00 +0100 5260910 http://www.medworm.com/index.php?rid=5260912&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01289.x Conclusion:  Capecitabine‐based chemotherapy strategies show prolonged OS and enhanced ORR compared with traditional 5‐FU‐based treatments and therefore should be considered as one of the first choices for treatment for AGC. Asian patients also showed less grade 3 or grade 4 gastrointestinal toxicity with the capecitabine‐based regimens. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5260912 Sun, 25 Sep 2011 04:00:00 +0100 5260912 http://www.medworm.com/index.php?rid=5260911&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01306.x Discussion:  The disease control rate was higher in the TPF group (92·9% vs. 76·5%), although the difference did not reach statistical significance (P = 0·217). Addition of docetaxel increased the median progression‐free survival to 435 days, which was 2·3 times longer than that (188 days) of patients not receiving docetaxel (P = 0·019). Non‐haematological toxicity profile was similar and acceptable in both treatment groups. Higher incidence of grade 3/4 neutropenia and more episodes of neutropenic fever‐related hospitalization occurred in the docetaxel‐treated patients, but most of them were managed uneventfully.What is new and conclusion:  Addition of dose‐modified docetaxel to cisplatin‐based induction chemotherapy was both efficacious and generally safe... Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5260911 Sun, 25 Sep 2011 04:00:00 +0100 5260911 http://www.medworm.com/index.php?rid=5225943&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01294.x This study also demonstrates the need for reassessment of wild‐type allele frequencies in view of CYP2C19*17 allele. The estimated high frequency of CYP2C19*17 allele will aid in genotype–phenotype association studies in the Tamilian population. Further genotype–phenotype association studies are required to evaluate the clinical utility of this allele in South Indians. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5225943 Sun, 18 Sep 2011 23:18:55 +0100 5225943 http://www.medworm.com/index.php?rid=5225944&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01298.x Conclusions:  This is first report of interethnic differences in frequencies of functional CYP2C19 and CYP2D6 genes among Chinese Mongolian, Hui and Han populations. These differences may be important in explaining reported inter‐ethnic differences in disease prevalence and response to drugs. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5225944 Wed, 14 Sep 2011 04:00:00 +0100 5225944 http://www.medworm.com/index.php?rid=5161936&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01293.x Conclusions:  Inappropriate antibiotic dispensing and use owing to commercial interests and lack of knowledge about the rational use of antibiotics and antibiotic resistance were the main findings of this in‐depth qualitative study. Community pharmacists were willing to participate in educational programme aimed at improving use of antibiotics. Such programmes should be initiated within a multidisciplinary framework including doctors, pharmacists, social scientists, government agencies and non‐profit organizations. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5161936 Mon, 22 Aug 2011 23:00:00 +0100 5161936 http://www.medworm.com/index.php?rid=5161935&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01296.x Conclusion:  The POP PK model we have developed for CBZ shows good predictive performance in Egyptian adult and pediatric patients with epilepsy. Another PK study to better define the effect of different covariates would improve on the model for dosage individualization. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5161935 Mon, 22 Aug 2011 23:00:00 +0100 5161935 http://www.medworm.com/index.php?rid=5097972&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01277.x Conclusion:  The evidence base suggests that the majority of medicines provided value for money. Such information informs policy decisions relating to the allocation of scarce health care resources in Europe. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5097972 Wed, 03 Aug 2011 23:00:00 +0100 5097972 http://www.medworm.com/index.php?rid=5161934&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01297.x Conclusion:  The present population pharmacokinetic analysis strongly indicates that fosfluconazole (and fluconazole) dosage should be optimized in terms of CLcr in critically ill patients. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5161934 Sun, 31 Jul 2011 23:00:00 +0100 5161934 http://www.medworm.com/index.php?rid=5144072&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01295.x Conclusions:  The available evidence suggests a beneficial effect of telmisartan in improving insulin sensitivity in hypertensive patients with insulin resistance or diabetes as demonstrated by the decrease in FPG and increase in adiponectin levels. The effect in decreasing FPG was greater with 80 mg dose than with the 40 mg dose. FPI and insulin resistance may be improved with 80 mg of telmisartan. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5144072 Sun, 31 Jul 2011 23:00:00 +0100 5144072 http://www.medworm.com/index.php?rid=5109590&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01292.x Conclusion:  The biological drugs used in rheumatoid arthritis are no different in efficacy. Their therapeutic positioning depends on their relative safety and convenience profiles. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5109590 Sun, 31 Jul 2011 23:00:00 +0100 5109590 http://www.medworm.com/index.php?rid=5097971&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01280.x Conclusion:  To the best of our knowledge, this is the first study investigating the effect of orlistat on insulin resistance and markers of inflammation. Orlistat improved lipid profile and led to faster glycaemic control and insulin resistance parameters than the control, without any serious adverse event. Orlistat also improved RBP‐4 and visfatin, effects not observed with placebo. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5097971 Sun, 31 Jul 2011 23:00:00 +0100 5097971 http://www.medworm.com/index.php?rid=5063928&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01281.x Conclusion:  A new hierarchical classification system for DRPs in the hospital setting has been developed. APS‐Doc seems suitable for various parts of the medication process such as medication reconciliation and drug therapy within both non‐surgical and surgical wards. Inter‐rater reliability was found to be substantial in the main categories and moderate in the subcategories. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5063928 Tue, 26 Jul 2011 17:13:55 +0100 5063928 http://www.medworm.com/index.php?rid=5052873&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01288.x Conclusion:  According to the findings of our small case series, liposomal amphotericin B may provide a useful treatment option for fungal infections of vulnerable critically ill paediatric patients with considerable comorbidity. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5052873 Sat, 23 Jul 2011 16:26:56 +0100 5052873 http://www.medworm.com/index.php?rid=5052874&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01279.x Conclusion:  Ethnicity was associated with significant differences in the single‐dose pharmacokinetics of losartan’s active carboxylic acid metabolite E‐3174 in healthy subjects of the five main ethnic groups in China. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5052874 Wed, 20 Jul 2011 23:00:00 +0100 5052874 http://www.medworm.com/index.php?rid=5039903&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01287.x Conclusion:  Individual courses of IVIg do not systematically raise blood pressure. Where IVIg is found to cause hypertension, this does not appear to be due to a direct effect of IVIg on plasma viscosity. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5039903 Wed, 20 Jul 2011 16:44:01 +0100 5039903 http://www.medworm.com/index.php?rid=5020912&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01285.x Conclusion:  Long‐acting beta‐agonists reduce the frequency of COPD exacerbations. Salmeterol, formoterol and indacaterol significantly reduced COPD exacerbations compared with placebo. Salmeterol but not formoterol decreased exacerbations significantly in the absence of ICS. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5020912 Wed, 13 Jul 2011 16:44:32 +0100 5020912 http://www.medworm.com/index.php?rid=5020914&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01286.x Conclusion:  Adding vitamins C and E to standard triple therapy increases the eradication rate of H. pylori. Vitamins C and E may increase the eradication rate via increasing the effectiveness of the antibiotics by decreasing oxidative stress in the gastric mucosa and strengthening the immune system. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5020914 Sun, 10 Jul 2011 23:00:00 +0100 5020914 http://www.medworm.com/index.php?rid=5020913&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01284.x Conclusion:  CB1‘selective’ antagonists and partial agonists have been studied for their anorexigenic and other potential therapeutic uses. An awareness of CB1‐independent mechanism(s) of these agents might contribute to a better understanding of the pharmacologic and toxicologic profiles of these agents. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5020913 Sun, 10 Jul 2011 23:00:00 +0100 5020913 http://www.medworm.com/index.php?rid=4999357&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01283.x Conclusion:  Exploring children/young people’s perspectives on the use of pump therapy for managing their diabetes, and parental reflections in caring for those children is important as it provides evidence informing policy for the wider implementation of this technology in the management of diabetes in children. However, the review revealed that there is a scarcity of data in this area and that further research is needed. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4999357 Wed, 06 Jul 2011 14:41:06 +0100 4999357 http://www.medworm.com/index.php?rid=4986295&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01278.x Conclusion:  Adefovir dipivoxil can be nephrotoxic at conventional dosage and therefore, patients treated with long‐term ADV should have regular monitoring of renal function, and calcium and phosphate levels. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4986295 Wed, 29 Jun 2011 23:00:00 +0100 4986295 http://www.medworm.com/index.php?rid=4986294&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01282.x Conclusion:  The CIOMS/RUCAM scale showed similar accuracy, but better reproducibility (agreement between observers) than the NARANJO scale, and therefore is recommended for use at pharmacovigilance centres. Fine‐tuning of the CIOMS/RUCAM method could contribute to better detection of unexpected hepatotoxicity. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4986294 Tue, 31 May 2011 23:00:00 +0100 4986294 http://www.medworm.com/index.php?rid=4842945&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01276.x Conclusions:  Based on a Medicaid population, patients treated with deferasirox were more compliant and persistent with their treatment than those treated with DFO. Frequency of hospitalizations was significantly reduced after treatment initiation for the any‐deferasirox and deferasirox‐only groups. Prospective studies controlling for potential clinical and treatment pattern differences between deferasirox and DFO patients are needed to assess whether the decreased hospitalizations after initiation of deferasirox are related to better treatment compliance. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4842945 Fri, 20 May 2011 15:58:56 +0100 4842945 http://www.medworm.com/index.php?rid=4831765&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01274.x Conclusions:  Pitavastatin was as effective as atorvastatin in lowering LDL‐C, TC and TG levels. Pitavastatin was marginally superior to atorvastatin in increasing HDL‐C levels. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4831765 Wed, 18 May 2011 17:00:01 +0100 4831765 http://www.medworm.com/index.php?rid=4842947&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01258.x SummaryWhat is known and objective:  Adverse drug reactions to prescribed medication are relatively common events. However, the impact such reactions have on patients and their attitude to reporting such events have only been poorly explored. Previous studies relying on self‐reporting patients indicate that altruism is an important factor. In the United Kingdom, patient reporting started in 2005; though, numbers of serious reports remain low.Method:  A purposive sample of fifteen patients who had been admitted to an inner city hospital with an adverse drug reaction were interviewed using a semi‐structured questionnaire. Patients were asked to relate in their own words their experience of an adverse drug reaction. Patient’s reactions to the information leaflet, adherence to treatm... Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4842947 Tue, 17 May 2011 23:00:00 +0100 4842947 http://www.medworm.com/index.php?rid=4842946&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01273.x Conclusion:  This first survey of awareness of the YCS in the general population of the UK indicates awareness is low and could be improved. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4842946 Tue, 17 May 2011 23:00:00 +0100 4842946 http://www.medworm.com/index.php?rid=4822151&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01275.x Conclusion:  Given that this reaction has rarely been reported, we discuss the present case with a review of other similar cases. Further studies are needed to substantiate this ‘signal alarm’ for serious MTX‐related hypersensitivity reactions. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4822151 Sat, 14 May 2011 18:26:10 +0100 4822151 http://www.medworm.com/index.php?rid=4763756&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01266.x Conclusion:  Medication‐related problems are frequent in renally compromised patients in our patient population. The high level of acceptance of clinical pharmacist’s recommendations by the nephrologists demonstrates that clinical pharmacists may help improve overall patient care in this setting. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4763756 Thu, 28 Apr 2011 23:00:00 +0100 4763756 http://www.medworm.com/index.php?rid=4755029&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01257.x Conclusions:  Using a novel UPLC‐MS/MS method, we showed that food intake affected the rate but not the extent of absorption of MGN within the 5‐ to 20‐mg dose range. Gender did not appear to affect the PK properties of MGN in either fasted or fed states. MGN should be preferably taken before food. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4755029 Sat, 23 Apr 2011 23:00:00 +0100 4755029 http://www.medworm.com/index.php?rid=4755028&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01269.x Conclusions:  MMF improved clinical laboratory markers and reduced prednisolone dosage in SLE patients with predose plasma concentration of MPA and MPAG in the interquartile ranges of 0·94–2·96 and 18·6–53·7 μg/mL, respectively. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4755028 Sat, 23 Apr 2011 23:00:00 +0100 4755028 http://www.medworm.com/index.php?rid=4755027&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01270.x Conclusions:  A high percentage (42·6%) of antimicrobial prescriptions among warfarin users were for high‐risk antimicrobials that carry excess bleeding risk. Although clinicians were somewhat less likely to prescribe high‐risk antimicrobials to warfarin users compared with non‐users, the incidence of co‐prescription remains high. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4755027 Sat, 23 Apr 2011 23:00:00 +0100 4755027 http://www.medworm.com/index.php?rid=4725795&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01249.x Conclusion:  Compounded 3,4‐DAP products are subject to considerable variability in active drug substance content. This variability seems to be principally because of heterogeneous formulated material rather than variation in dosage form weight. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4725795 Mon, 18 Apr 2011 23:00:00 +0100 4725795 http://www.medworm.com/index.php?rid=4725794&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01261.x Conclusion:  A majority of patients with SCD had sub‐optimal SGC. The pharmacokinetic profile of such patients is apparently too variable to fit the existing Hartford protocol. The Hartford nomogram should be modified to address this issue. Otherwise, clinicians should revert to multiple daily dosing. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4725794 Mon, 18 Apr 2011 23:00:00 +0100 4725794 http://www.medworm.com/index.php?rid=4725793&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01264.x Conclusion:  We suggest that multi‐mechanistic analgesia, accomplished within either a single drug or a combination of drugs, is a logical approach that might result in a reduced development of OIH. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4725793 Mon, 18 Apr 2011 23:00:00 +0100 4725793 http://www.medworm.com/index.php?rid=4725792&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01265.x Conclusion:  Despite the limited evidence that supplements ameliorate symptoms of schizophrenia, given the low risk of harm, some clinicians might opt to add omega‐3 polyunsaturated fatty acid to current drug regimens in hope of better symptomatic control in schizophrenia. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4725792 Mon, 18 Apr 2011 23:00:00 +0100 4725792 http://www.medworm.com/index.php?rid=4677694&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01267.x Conclusion:  This is the first report of the use of edaravone in ALD. The drug is apparently effective in improving symptoms of ALD and should be evaluated more formally. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4677694 Sun, 03 Apr 2011 23:00:00 +0100 4677694 http://www.medworm.com/index.php?rid=4782718&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01272.x Conclusion:  Our results suggest that ITPA 94C>A testing, but not TPMT testing, may help in minimizing the adverse effects of 6‐MP in Malaysian patients. However, whether this is true in clinical practice requires a larger study and formal randomized controlled evaluation. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4782718 Thu, 31 Mar 2011 23:00:00 +0100 4782718 http://www.medworm.com/index.php?rid=4763755&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01268.x Conclusions:  CYP3A4*1G has an impact on the analgesic effect of fentanyl in Chinese Han subjects. Further validation of our results in a well‐powered study would be helpful. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4763755 Thu, 31 Mar 2011 23:00:00 +0100 4763755 http://www.medworm.com/index.php?rid=4755026&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01271.x Conclusion:  The pharmacokinetics of risperidone was affected by the concomitant administration of ketoconazole. If a CYP3A4 inhibitor is used concomitantly with risperidone, it is necessary for the clinicians to monitor their patients for signs of adverse drug reactions. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4755026 Thu, 31 Mar 2011 23:00:00 +0100 4755026 http://www.medworm.com/index.php?rid=4736245&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01262.x Conclusion:  This study identifies factors which affect warfarin dosing in the Malaysia population. However, our best model does not account sufficiently for the variability in dose requirements for it to be used in dose prediction for the individual patient. Other important influential factors affecting warfarin dose requirement remain to be identified. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4736245 Thu, 31 Mar 2011 23:00:00 +0100 4736245 http://www.medworm.com/index.php?rid=4725791&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01260.x Conclusion:  Any effective cancer therapy can lead to TLS. Physicians should consider the risk of TLS on a case‐by‐case basis and determine appropriate prophylaxis. The role of rasburicase continues to evolve. Randomized controlled trials evaluating clinically relevant outcomes are needed. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4725791 Thu, 31 Mar 2011 23:00:00 +0100 4725791 http://www.medworm.com/index.php?rid=4686564&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01256.x Conclusion:  Effective therapy needs good prescribing and well‐informed prescribers and patients. Our study highlights wide differences in analgesic consumption even among similar European countries. The basis of these differences and their potential clinical impact require further investigation. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4686564 Thu, 31 Mar 2011 23:00:00 +0100 4686564 http://www.medworm.com/index.php?rid=4677693&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01263.x We report a case where the critical error was discovered by the community pharmacist during the routine implementation of the Pharmaceutical Care process SOAP while dispensing a new prescription for the patient.Details of the case:  A 78‐year‐old widow went to her regular community pharmacy to pick up a prescription for oral mucositis. The evaluation of the case by the pharmacist using the SOAP (an acronym for Subjective, Objective, Assessment and Plan) note method revealed the underlying oral low‐dose MTX intoxication which led to hospitalization a few days later. The incorrect interpretation of the required dose had arisen from the written instructions for use and led to the erroneous intake of MTX daily (instead of weekly). We interviewed the patient at her home 2 months after... Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4677693 Thu, 31 Mar 2011 23:00:00 +0100 4677693 http://www.medworm.com/index.php?rid=4671735&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01259.x SummaryWhat is known and Objective:  Intravenous sodium stibogluconate (SbV) is the mainstay of treatment for mucocutaneous leishmaniasis. Incidence of this disease is increasing in the UK, partly because of returning military personnel. SbV has a side effect profile that requires treatment interruption in up to 28% of patients. Side effects can be unpleasant and – in the case of QTc prolongation – dangerous.Case summary:  A volunteer medical worker returning from Guatemala was diagnosed with mucocutaneous leishmaniasis. Because of previous renal problems, NSAIDs were contraindicated. Severe side effects of myalgia and arthralgia would have necessitated a treatment interruption, but a trial of prednisolone gave excellent symptomatic relief. The patient’s QTc, amylase and C‐reac... Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4671735 Thu, 31 Mar 2011 23:00:00 +0100 4671735 http://www.medworm.com/index.php?rid=4616815&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01255.x Conclusion:  There is limited evidence for the efficacy of metformin in limiting weight‐gain induced by atypical antipsychotic agents. However, the evidence is weak and further well‐powered randomized, double‐blind, placebo‐controlled studies of longer duration should be conducted to confirm the preliminary evidence and provide better estimates of effect. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4616815 Tue, 22 Mar 2011 16:54:28 +0100 4616815 http://www.medworm.com/index.php?rid=4606818&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01254.x SummaryWhat is known and objective:  Muscle toxicity is the most significant adverse effect related to statins. The aim of the study was to analyse the clinical course and achievement of LDL‐C target levels in patients with statin‐induced muscle toxicity.Methods:  All patients who were referred to the lipid clinic because of statin‐induced muscle toxicity, or developed it during follow‐up, or did not reach LDL‐C target levels because of its previous occurrence, and attended the clinic for at least three follow‐up visits, were eligible. Files were reviewed for demographic and clinical parameters, coronary heart disease risk level, the severity of muscle injury, the type of statin and dose that caused the adverse effects, the clinical approach and outcome, and whether the LDL... Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4606818 Fri, 18 Mar 2011 16:37:43 +0100 4606818 http://www.medworm.com/index.php?rid=4601599&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01252.x Conclusion:  The injection combinations of morphine sulphate and levomepromazine hydrochloride were shown in the current study to have a limited storage life with respect to their levomepromazine hydrochloride content. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4601599 Thu, 17 Mar 2011 16:40:16 +0100 4601599 http://www.medworm.com/index.php?rid=4601601&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01250.x Conclusions  We found that lower out‐of‐pocket expenses associated with the initiating statin had a positive impact on persistence with therapy. The finding does not seem to apply to persons with minor copayments towards the end of the initiation year. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4601601 Wed, 16 Mar 2011 00:00:00 +0100 4601601 http://www.medworm.com/index.php?rid=4601600&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01251.x Conclusion:  Our data suggest that modulation of Akt‐GSK3β pathway is involved in the cell death pathway engaged by TZDs in prostate cancer cells. This reveals another possible mechanism of TZDs on apoptosis in prostate cancer. Inhibition of the Akt‐GSK3β cascade may be a useful approach in prostate cancer. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4601600 Wed, 16 Mar 2011 00:00:00 +0100 4601600 http://www.medworm.com/index.php?rid=4581848&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01253.x Conclusion:  Calcium channel blocker treatment of patients with gastrointestinal disease was associated with alteration in frequency of prescription and an increase in dosage of antisecretory drugs. For clinical management of hypertension, alternative antihypertensive drugs may be considered for patients with gastrointestinal diseases. Further studies are required to determine the influence of CCB therapy on gastroesophageal diseases, suggested by the increase in use of antisecretory drugs. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4581848 Mon, 14 Mar 2011 17:55:52 +0100 4581848 http://www.medworm.com/index.php?rid=4561823&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01248.x Conclusion:  Despite the small sample size, our results suggest that genetic variation in leukotriene pathway candidate genes contributes to variability in clinical responses to montelukast in Japanese patients with asthma. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4561823 Wed, 09 Mar 2011 16:39:09 +0100 4561823 http://www.medworm.com/index.php?rid=4536799&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01236.x This study examined the ability of an algorithm applied to urine drug levels of hydrocodone in healthy adult volunteers to differentiate among low, medium and high doses of hydrocodone.Methods:  Twenty healthy volunteers received 20, 60 and 120 mg daily doses of hydrocodone dosed to steady‐state at each level while under a naltrexone blockade. Using a florescence polarization immunoassay (FPIA), two urine samples were taken at each dosing level from each participant once steady‐state was reached. The concordance was calculated for raw and adjusted FPIA urine hydrocodone values within each study participant across all doses. An analysis of medians was calculated for each of the dosage groupings using Bonett‐Price confidence intervals for both raw and adjusted FPIA values. Finally,... Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4536799 Wed, 02 Mar 2011 17:41:22 +0100 4536799 http://www.medworm.com/index.php?rid=4536798&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01221.x SummaryWhat is known and objective:  Worldwide studies have shown that significant proportions of patients with type 2 diabetes (T2DM) do not meet targets for glycaemic control, blood pressure (BP) and lipids, putting them at higher risk of developing complications. However, little is known about medicines management in Australian primary care populations with T2DM. The aim of this study was to (i) describe the management of a large group of patients in primary care, (ii) identify areas for improvement in management and (iii) determine any relationship between adherence and glycaemic, BP and lipid control.Methods:  This was a retrospective, epidemiological study of primary care patients with T2DM diabetes, with HbA1c of >7%, recruited in 90 Australian community pharmacies. Data coll... Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4536798 Wed, 02 Mar 2011 17:40:44 +0100 4536798 http://www.medworm.com/index.php?rid=4490811&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01245.x Conclusion:  We provide a critical review of the impact of PMPs on the use of BZDs. PM decreases overall use of BZDs, but may have unintended consequences that differentially impact certain populations. Furthermore, research is warranted to understand better the long‐term costs and benefits. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4490811 Thu, 17 Feb 2011 00:00:00 +0100 4490811 http://www.medworm.com/index.php?rid=4490810&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01246.x Conclusion:  Miconazole oral gel and topically applied nystatin solution have equally strong effects on warfarin activity and can provoke major bleeding. Prospective evaluation of this effect is called for. However, based on our results the warfarin dose adjustment appears necessary when the anticoagulant is used concomitantly with those topical antifungals. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4490810 Thu, 17 Feb 2011 00:00:00 +0100 4490810 http://www.medworm.com/index.php?rid=4490809&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01247.x Conclusion:  In the present study, we found the first evidence that renal impairment in the first week after LRN was a risk factor of hypoglycaemia. To prevent hypoglycaemia after LRN, assessment of renal function and the use of insulin therapy are important. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4490809 Tue, 01 Feb 2011 00:00:00 +0100 4490809 http://www.medworm.com/index.php?rid=4446732&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01241.x Conclusion:  This analysis confirms the association between the use of antibiotics and the prevalence of resistance in a surgical clinic. Surveillance of bacterial resistance should be done periodically according to local guidelines for antibiotic therapy of surgical infections, as well as for external comparison. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4446732 Tue, 01 Feb 2011 00:00:00 +0100 4446732 http://www.medworm.com/index.php?rid=4442820&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01242.x Conclusion:  The availability of information systems offers the opportunity to monitor the quality of care and identify weaknesses in public health‐care systems. Our results identify specific factors contributing to non‐adherence and hence define areas for more targeted health‐care interventions. Our results suggest that efforts to improve adherence should focus on women and older patients. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4442820 Tue, 01 Feb 2011 00:00:00 +0100 4442820 http://www.medworm.com/index.php?rid=4415515&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2011.01244.x Conclusion:  We highlight the inadequacy of current approaches for lowering Lp(a) and draw attention to novel insights that may lead to better treatment. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4415515 Mon, 31 Jan 2011 15:39:15 +0100 4415515 http://www.medworm.com/index.php?rid=4415516&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01243.x Conclusion:  A rapid and validated isocratic fluorometric HPLC method for the determination of gabapentin in human plasma and urine for clinical application has been established. This method can be utilized to evaluate the pharmacokinetic disposition of gabapentin in humans. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4415516 Sun, 30 Jan 2011 00:00:00 +0100 4415516 http://www.medworm.com/index.php?rid=4356526&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01240.x Conclusion:  We draw attention to the increasing range of diseases, including diabetes and obesity, associated with our microbiome. This pharmacogenetic example reminds us that in personalised medicine, there is more than our own genome to take account of. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4356526 Mon, 17 Jan 2011 18:34:21 +0100 4356526 http://www.medworm.com/index.php?rid=4314949&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01239.x Conclusion:  Patients with bone‐cancer pain, already on opioids, obtain clinically important, additional pain‐control, with regular oxycodone/paracetamol dosing. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4314949 Thu, 06 Jan 2011 17:41:20 +0100 4314949 http://www.medworm.com/index.php?rid=4310449&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01237.x Conclusion:  Co‐administration of VCE restored antioxidant status, lowered by the presence of breast‐cancer and chemotherapy. DNA damage was also reduced by VCE. The results suggest that VCE should be useful in protecting against chemotherapy‐related side‐effects and a randomized control trial to evaluate the effectiveness of VCE in breast‐cancer patients using clinical outcomes would be appropriate. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4310449 Wed, 05 Jan 2011 17:33:38 +0100 4310449 http://www.medworm.com/index.php?rid=4314950&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01238.x Conclusion:  This study is the first examination of CYP2C9*3 homozygotes in the Korean population. Our data on the one subject with this genotype suggest that CYP2C9*3/*3 momozygotes have lower clearance of glimepiride and are exposed to higher levels of the drug than wild‐type homozygotes. Although we identified a subject with the CYP2C9*13 allele using a new pyrosequencing assay, we were unfortunately unable to investigate its effects on glimepiride pharmacokinetics. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4314950 Wed, 05 Jan 2011 00:00:00 +0100 4314950 http://www.medworm.com/index.php?rid=4282229&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01231.x Conclusion:  Retreatment with peginterferon plus ribavirin is an effective option for some chronic hepatitis C non‐responder or relapser patients. Higher SVR rate was achieved in relapsers and in those patients who received IFNα monotherapy previously. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4282229 Wed, 22 Dec 2010 00:00:00 +0100 4282229 http://www.medworm.com/index.php?rid=4273005&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01236.x This study examined the ability of an algorithm applied to urine drug levels of hydrocodone in healthy adult volunteers to differentiate among low, medium and high doses of hydrocodone.Methods:  Twenty healthy volunteers received 20, 60 and 120 mg daily doses of hydrocodone dosed to steady‐state at each level while under a naltrexone blockade. Using a florescence polarization immunoassay (FPIA), two urine samples were taken at each dosing level from each participant once steady‐state was reached. The concordance was calculated for raw and adjusted FPIA urine hydrocodone values within each study participant across all doses. An analysis of medians was calculated for each of the dosage groupings using Bonett‐Price confidence intervals for both raw and adjusted FPIA values. Finally,... Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4273005 Sun, 19 Dec 2010 00:00:00 +0100 4273005 http://www.medworm.com/index.php?rid=4254225&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01222.x SummaryWhat is known and objective:  The importance of statistical power is widely recognized from a pre‐trial perspective, and when interpreting results that are not statistically significant. It is less well recognized that poor power can lead to inflated estimates of the effect size when statistically significant results are observed. We use trial simulations to quantify this bias, which we term ‘significant‐result bias’.Comment:  Significant‐result bias is explained, and simulations are used to estimate possible significant‐result bias in the rate of thrombotic events observed in the APPROVe trial. Statistically significant results, on outcomes for which there is empirical evidence of poor power, may provide inflated estimates of the size of effect.What is new and concl... Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4254225 Sun, 12 Dec 2010 00:00:00 +0100 4254225 http://www.medworm.com/index.php?rid=4254224&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01226.x Conclusion:  We present a model for estimating blood–alcohol levels from breath‐alcohol measurements. The results of our study are useful particularly in relation to drink‐driving prosecutions because of the routine use of breath‐alcohol measurements as evidence in such cases through the world. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4254224 Sun, 12 Dec 2010 00:00:00 +0100 4254224 http://www.medworm.com/index.php?rid=4254223&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01228.x Conclusion:  CUSUM, a statistical process control technique, has already been tested as a tool for interpreting hospital and general practice mortality rates. Here, its potential for more general applications in quality monitoring is demonstrated using routinely collected prescribing data. Such data contain valuable information about changes in clinical practice and CUSUM charts, when coupled with the idea of removing time trends and extraneous variation by reference to average behaviour, can provide a simple but effective technique for extracting it. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4254223 Sun, 12 Dec 2010 00:00:00 +0100 4254223 http://www.medworm.com/index.php?rid=4242608&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01218.x Conclusion:  This study provides new evidence, from a randomized controlled trial, of the beneficial effect of community pharmacist intervention in the clinical management of type 2 diabetic patients. However, questions remain about the sustainability of the observed improvements. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4242608 Wed, 08 Dec 2010 00:00:00 +0100 4242608 http://www.medworm.com/index.php?rid=4242607&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01229.x Conclusion:  We summarize all reported, clinically significant, cases of drug interaction between miconazole oral gel and warfarin. Pharmacokinetic modelling shows that concomitant administration of warfarin and miconazole oral gel can lead to substantial increase in warfarin concentration. However, our PK/PD model fails to capture the dramatic increases seen in INR values, and hence bleeding complications, reported in the literature. Taken together, the evidence suggests that concomitant use of miconazole gel and warfarin should be avoided. Even over‐the‐counter products containing miconazole should be used with caution by patients receiving warfarin. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4242607 Wed, 08 Dec 2010 00:00:00 +0100 4242607 http://www.medworm.com/index.php?rid=4230904&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01234.x Conclusion:  Although ETN is often regarded as safe for patients with ILD, our case and the literature reports suggest that caution is still required. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4230904 Sun, 05 Dec 2010 00:00:00 +0100 4230904 http://www.medworm.com/index.php?rid=4230903&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01235.x Conclusion:  Concomitant administration of BILR 355 with 3TC/ZDV resulted in a modest decrease in exposure to BILR 355 and a 45% increase in exposure to 3TC. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4230903 Sun, 05 Dec 2010 00:00:00 +0100 4230903 http://www.medworm.com/index.php?rid=4226461&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01227.x Conclusion:  The CYP7A1 ‐204A and ABCG8 1199A alleles appear to interact to affect lipid‐lowering response to atorvastatin. However, given the relatively small number of subjects with the influential variant allele combinations, and the heterogeneity in response, even in the selected sub‐populations, testing would be of little clinical utility in the Chinese population sampled. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4226461 Fri, 03 Dec 2010 00:00:00 +0100 4226461 http://www.medworm.com/index.php?rid=4226460&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01232.x Conclusion: CYP3A4*4 and CYP3A4*5 are rare in the Malaysian Malay population. Genetic polymorphism of CYP3A4*18 may not play an important role in influencing postoperative fentanyl requirements. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4226460 Fri, 03 Dec 2010 00:00:00 +0100 4226460 http://www.medworm.com/index.php?rid=4208785&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01230.x SummaryWhat is known and Objective:  Poor insight is prevalent among patients with schizophrenia and improved insight is one of the major goals of treatment. The purpose of the present study was to examine the relationship between insight and subjective well‐being during acute treatment of schizophrenia with atypical antipsychotics in a naturalistic clinical setting.Methods:  Forty inpatients with schizophrenia were examined before and 8 weeks after the initiation of new treatment with atypical antipsychotics.Results:  There were significant correlations between changes in insight and those in psychopathology and global functioning. The change in insight score was significantly correlated with that in subjective well‐being score, indicating that the improvement in insight was p... Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4208785 Sun, 28 Nov 2010 00:00:00 +0100 4208785 http://www.medworm.com/index.php?rid=4208784&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01233.x Conclusion:  Flurpirtine might represent a novel class of analgesic agent. As such, it could be useful for the treatment of types of pains normally not amenable to conventional (NSAID or opioid) pharmacotherapy. It could also spawn new avenues of analgesic drug discovery efforts. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4208784 Sun, 28 Nov 2010 00:00:00 +0100 4208784 http://www.medworm.com/index.php?rid=4197974&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01224.x Conclusion:  Our results suggest that the inhibition of topoisomerases may be a significant factor in imatinib‐induced apoptosis in CML. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4197974 Thu, 25 Nov 2010 04:31:33 +0100 4197974 http://www.medworm.com/index.php?rid=4201126&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01199.x Conclusion:  This strategy was well tolerated, and the C3 for twice‐daily infusion and the C8 for oral administration were the optimal points for monitoring of CyA concentration in the early phase of transplantation. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4201126 Thu, 25 Nov 2010 00:00:00 +0100 4201126 http://www.medworm.com/index.php?rid=4176323&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01225.x Conclusion:  Green discoloration of the urine from propofol infusion is dose dependent. It is usually benign and reversible, as was the case for our patient. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4176323 Thu, 18 Nov 2010 05:27:31 +0100 4176323 http://www.medworm.com/index.php?rid=4160261&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01217.x Conclusion:  Sibutramine resulted in a decrease in body weight at 9 months and at 12 months that was not observed with placebo. Although there were differences seen over time within each of the groups, there were no significant differences between groups for any other parameter that we measured. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4160261 Sat, 13 Nov 2010 04:12:07 +0100 4160261 http://www.medworm.com/index.php?rid=4160262&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01216.x Conclusion:  Inpatient anticoagulation care and outcomes were significantly improved by a pharmacist‐managed anticoagulation service. The time to therapeutic INR was achieved appropriately and efficiently without compromising patient’s safety. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4160262 Fri, 12 Nov 2010 00:00:00 +0100 4160262 http://www.medworm.com/index.php?rid=4152810&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01215.x Conclusion:  Our validation results suggest good predictive performance of the population models developed earlier, and quite acceptable predictions of future AED serum levels for individualized dosage regimens of CBZ and VPA therapy in real clinical settings. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4152810 Thu, 11 Nov 2010 02:50:00 +0100 4152810 http://www.medworm.com/index.php?rid=4145005&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01223.x This study investigated the effect of SJW on the pharmacokinetics of zolpidem in healthy subjects.Methods:  A controlled, open‐label, non‐randomized, fixed‐dose schedule design was used. Fourteen healthy male subjects received a single 10 mg oral dose of zolpidem followed by SJW administration (300 mg orally, three times a day) for 14 days; the last dose of SJW was coadministered with a single dose of zolpidem. Blood samples were obtained over a 24‐h period after zolpidem administration. Pharmacokinetic data for zolpidem alone and in combination with SJW were analysed by high‐performance liquid chromatography.Results:  After repeated administration of SJW, the mean values of AUC and Cmax for zolpidem significantly decreased (380·3 ± 181·4 vs. 265·4 ± 134·2�... Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4145005 Wed, 10 Nov 2010 04:02:24 +0100 4145005 http://www.medworm.com/index.php?rid=4152814&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01211.x Conclusion:  Despite the values of RLAT in treating patients with schizophrenia, RLAT is largely underutilized in routine clinical practice. This observation highlights the importance for future research to ascertain the cost‐effectiveness of initiating RLAT, especially the extent to which medication adherence influences the prescription pattern of RLAT and subsequent costs of initiating RLAT. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4152814 Wed, 10 Nov 2010 00:00:00 +0100 4152814 http://www.medworm.com/index.php?rid=4152813&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01212.x Conclusion:  The combination of EP, zinc, selenium and vitamin C may alleviate exacerbation symptoms caused by URTI in COPD. Further studies are warranted to investigate the interactions among Echinacea, zinc, selenium and vitamin C. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4152813 Wed, 10 Nov 2010 00:00:00 +0100 4152813 http://www.medworm.com/index.php?rid=4152812&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01213.x Conclusion:  The formulation and implementation of the BZD guidelines appear not to be associated with a reduced rate of sole prescribing of BZDs for major depression, and more comprehensive efforts are required. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4152812 Wed, 10 Nov 2010 00:00:00 +0100 4152812 http://www.medworm.com/index.php?rid=4152811&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01214.x Conclusion:  Voriconazole appears to be effective as monotherapy for the treatment of pulmonary W. dermatitidis infections. A minimum of 3–4 months of antifungal treatment should be given. Adverse effects with prolonged voriconazole use do not appear to be a barrier to treatment. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4152811 Wed, 10 Nov 2010 00:00:00 +0100 4152811 http://www.medworm.com/index.php?rid=4135645&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2009.01127.x Conclusions:  The multiplex pyrosequencing method used to detect two ABCG2 polymorphisms concurrently is a rapid and reliable genotyping method for the detection of important ABCG2 genetic polymorphisms. The ABCG2 34G>A and 421C>A polymorphisms are frequently found in the Korean population. The frequencies are similar to those seen in other Asian populations including Japanese and Chinese, but very different to those of Caucasian and African‐American populations. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4135645 Fri, 05 Nov 2010 19:13:25 +0100 4135645 http://www.medworm.com/index.php?rid=4135644&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2009.01139.x Conclusion:  There was belief by those Australians surveyed that community pharmacists are capable of providing screening for hypertension and diabetes. Through these services and in conjunction with counselling on CVD risk reduction, pharmacists may play an important role in the reduction of CVD, ultimately improving public health and decreasing the burden on Australia’s health care system. However, at present pharmacists are not being fully utilized to deliver health promotion advice and contribute to the prevention of CVD. (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4135644 Fri, 05 Nov 2010 19:13:23 +0100 4135644 http://www.medworm.com/index.php?rid=4135642&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01220.x This study was conducted to establish the role of patient characteristics in estimating doses of phenobarbital for neonates and infants using routine therapeutic drug monitoring data.Methods:  The population pharmacokinetics of phenobarbital was evaluated using 109 serum concentration measurements obtained from routine phenobarbital monitoring of 70 neonates and infants. The data were analysed using the non‐linear mixed effects model. A one‐compartment pharmacokinetic model with first‐order elimination was used. Covariates screened were current total bodyweight (TBW), gestational age, postnatal age (PNA), post‐conceptional age, gender and neonates‐infants clearance factor (serum concentration of phenobarbital; Conc).Results and discussion:  The final pharmacokinetic parameter... Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4135642 Fri, 05 Nov 2010 19:12:57 +0100 4135642 http://www.medworm.com/index.php?rid=4135643&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01219.x SummaryWhat is known and objective:  Long‐acting injectable (LAI) antipsychotics are recommended for those people with a preference for this form of treatment and those who experience negative outcomes due to non‐adherence with oral medication. LAI antipsychotics have been associated with improved outcomes and lower treatment discontinuation rates when compared with oral formulations. Risperidone long‐acting injection (RLAI) treatment is effective and well‐tolerated in clinical trials. The aim of this study was to review RLAI prescribing practice and compare prescribing to best practice recommendations (including indication, initiation, dose and co‐prescribing) for adults receiving care from five clinical practice settings of New Zealand.Methods:  Patients starting publicly f... Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4135643 Fri, 05 Nov 2010 00:00:00 +0100 4135643 http://www.medworm.com/index.php?rid=4110173&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01202.x Summary (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4110173 Thu, 30 Sep 2010 23:00:00 +0100 4110173 http://www.medworm.com/index.php?rid=4110172&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01204.x Summary (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4110172 Thu, 30 Sep 2010 23:00:00 +0100 4110172 http://www.medworm.com/index.php?rid=4110171&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01205.x Summary (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4110171 Thu, 30 Sep 2010 23:00:00 +0100 4110171 http://www.medworm.com/index.php?rid=4110170&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01209.x Summary (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4110170 Thu, 30 Sep 2010 23:00:00 +0100 4110170 http://www.medworm.com/index.php?rid=4110169&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01210.x Summary (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4110169 Thu, 30 Sep 2010 23:00:00 +0100 4110169 http://www.medworm.com/index.php?rid=4083006&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01185.x Summary (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4083006 Thu, 30 Sep 2010 23:00:00 +0100 4083006 http://www.medworm.com/index.php?rid=4083005&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01190.x Summary (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4083005 Thu, 30 Sep 2010 23:00:00 +0100 4083005 http://www.medworm.com/index.php?rid=4078480&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01160.x Summary (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4078480 Thu, 30 Sep 2010 23:00:00 +0100 4078480 http://www.medworm.com/index.php?rid=4078479&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01176.x Summary (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4078479 Thu, 30 Sep 2010 23:00:00 +0100 4078479 http://www.medworm.com/index.php?rid=4078478&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01179.x Summary (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4078478 Thu, 30 Sep 2010 23:00:00 +0100 4078478 http://www.medworm.com/index.php?rid=4078477&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01186.x Summary (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4078477 Thu, 30 Sep 2010 23:00:00 +0100 4078477 http://www.medworm.com/index.php?rid=4078476&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01187.x Summary (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4078476 Thu, 30 Sep 2010 23:00:00 +0100 4078476 http://www.medworm.com/index.php?rid=4078475&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01189.x Summary (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4078475 Thu, 30 Sep 2010 23:00:00 +0100 4078475 http://www.medworm.com/index.php?rid=4078474&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01191.x Summary (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4078474 Thu, 30 Sep 2010 23:00:00 +0100 4078474 http://www.medworm.com/index.php?rid=4078473&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01198.x Summary (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4078473 Thu, 30 Sep 2010 23:00:00 +0100 4078473 http://www.medworm.com/index.php?rid=4078472&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01195.x Summary (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4078472 Thu, 30 Sep 2010 23:00:00 +0100 4078472 http://www.medworm.com/index.php?rid=4078471&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01200.x Summary (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4078471 Thu, 30 Sep 2010 23:00:00 +0100 4078471 http://www.medworm.com/index.php?rid=4032687&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01206.x Summary (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4032687 Thu, 30 Sep 2010 23:00:00 +0100 4032687 http://www.medworm.com/index.php?rid=4014679&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01207.x Summary (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4014679 Thu, 30 Sep 2010 14:02:58 +0100 4014679 http://www.medworm.com/index.php?rid=3962996&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2009.01118.x Summary (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=3962996 Tue, 14 Sep 2010 05:45:52 +0100 3962996 http://www.medworm.com/index.php?rid=3962995&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2009.01116.x Summary (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=3962995 Tue, 14 Sep 2010 05:45:51 +0100 3962995 http://www.medworm.com/index.php?rid=3962994&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2009.01114.x Abstract (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=3962994 Tue, 14 Sep 2010 05:45:51 +0100 3962994 http://www.medworm.com/index.php?rid=3962993&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2009.01128.x Summary (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=3962993 Tue, 14 Sep 2010 05:45:50 +0100 3962993 http://www.medworm.com/index.php?rid=3962992&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2009.01142.x Summary (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=3962992 Tue, 14 Sep 2010 05:45:50 +0100 3962992 http://www.medworm.com/index.php?rid=3962991&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2009.01133.x Abstract (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=3962991 Tue, 14 Sep 2010 05:45:50 +0100 3962991 http://www.medworm.com/index.php?rid=3962990&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2009.01132.x Summary (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=3962990 Tue, 14 Sep 2010 05:45:49 +0100 3962990 http://www.medworm.com/index.php?rid=3962989&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2009.01131.x Summary (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=3962989 Tue, 14 Sep 2010 05:45:49 +0100 3962989 http://www.medworm.com/index.php?rid=3962988&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2009.01129.x Abstract (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=3962988 Tue, 14 Sep 2010 05:45:48 +0100 3962988 http://www.medworm.com/index.php?rid=3962987&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2009.01126.x Summary (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=3962987 Tue, 14 Sep 2010 05:45:48 +0100 3962987 http://www.medworm.com/index.php?rid=3962986&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2009.01095.x Summary (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=3962986 Tue, 14 Sep 2010 05:45:48 +0100 3962986 http://www.medworm.com/index.php?rid=3962985&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2009.01107.x Summary (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=3962985 Tue, 14 Sep 2010 05:45:47 +0100 3962985 http://www.medworm.com/index.php?rid=4014680&cid=s_32543_13_f&fid=32543&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2710.2010.01182.x Summary (Source: Journal of Clinical Pharmacy and Therapeutics) Journal of Clinical Pharmacy and Therapeutics journals http://www.medworm.com/rss/comments.php?id=4014680 Tue, 31 Aug 2010 23:00:00 +0100 4014680